Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Retrospective analysis (n=93 at single centre) found anti-SARS-CoV-2 IgG in 56% of patients after their first vaccination, rising to 70% when measuring total antibody, a rate that is lower than in the vaccine trials, in which serological response is almost universal.

Source:

The Lancet Haematology